PTC Therapeutics PTCT EBITDA

EBITDA at other companies

Sarepta Therapeutics, Inc.SRPT

$23.7M-81.3%

BioMarin PharmaceuticalsBMRN

$208.56M-29.4%

Capricor TherapeuticsCAPR

-$36.24M-47.4%

ALN

Alnylam PharmaceuticalsALNY

$245.34M+10,980%

Edgewise Therapeutics, Inc.EWTX

-$53.58M-17.9%

Dyne Therapeutics, Inc.DYN

-$124.73M-2.3%

FAQ

What is PTC Therapeutics's EBITDA?

PTC Therapeutics (PTCT) reported EBITDA of $60.37M in Q1 2026.

How has PTC Therapeutics's EBITDA changed year-over-year?

PTC Therapeutics's EBITDA decreased by 93.8% year-over-year, from $977.45M to $60.37M.

What is the long-term trend for PTC Therapeutics's EBITDA?

Over 4 years (2021 to 2025), PTC Therapeutics's EBITDA has grown at a 33.2% compound annual growth rate (CAGR), from -$310.31M to $977.1M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.